紫杉醇脂质体与紫杉醇注射液治疗晚期卵巢癌的疗效及安全性比较

Comparison of efficacy and safety between paclitaxel liposome and paclitaxel injection in the treatment of advanced ovarian cancer

目的 比较紫杉醇脂质体与紫杉醇注射液治疗晚期卵巢癌的疗效及安全性。方法 回顾性选取2016年8月—2018年8月于福州市第二总医院确诊并治疗的晚期卵巢癌患者67例,根据治疗方法不同分为观察组(n=34)和对照组(n=33)。观察组给予紫杉醇脂质体联合顺铂治疗,对照组给予紫杉醇注射液联合顺铂治疗,21 d为1个周期,2组均治疗4个周期。比较2组临床疗效、生活质量及不良反应,随访至2021年8月,比较2组生存率。结果 观察组客观缓解率(ORR)为47.06%,对照组ORR为48.48%,2组比较差异无统计学意义(χ^(2)=0.014,P=0.907)。治疗4个周期后,观察组生活质量评级优于对照组(Z=2.100,P=0.039)。观察组不良反应总发生率为55.88%,低于对照组的84.85%(χ^(2)=6.709,P=0.010)。随访至2021年8月,观察组平均随访时间33个月,随访期间死亡10例;对照组平均随访时间31个月,随访期间死亡14例。通过Kaplan-Meier法对患者进行生存分析,观察组生存率为70.59%(24/34),高于对照组的57.58%(19/33),但差异无统计学意义(χ^(2)=0.732,P=0.392)。结论 紫杉醇脂质体与紫杉醇注射液治疗晚期卵巢癌的疗效相当,但紫杉醇脂质体较紫杉醇注射液更安全,不良反应发生率更低,化疗后患者生活质量更高,生存时间更长。

Objective To compare the efficacy and safety of paclitaxel liposome and paclitaxel injection in the treatment of advanced ovarian cancer.Methods sixty-seven patients with advanced ovarian cancer who were diagnosed and treated in Fuzhou Second General Hospital from August 2016 to August 2018 were retrospective selected,and they were divided into observation group(n=34)and control group(n=33)according to the different treatment methods.The observation group was given paclitaxel liposome combined with cisplatin treatment,and the control group was given paclitaxel injection combined with cisplatin treatment,21 d as 1 treatment cycle,and both groups were treated for 4 cycles.The clinical efficacy,quality of life,and adverse reactions of the two groups were compared,follow-up until August 2021,the survival rates of the two groups were compared.Results The objective remission rate was 47.06%in the observation group and 48.48%in the control group,and the difference between the two groups was not statistically significant(χ^(2)=0.014,P=0.907).After 4 cycles of treatment,the quality of life rating of the observation group was better than that of the control group(Z=2.100,P=0.039).The total incidence of adverse reactions in the observation group was 55.88%,was lower than 84.85%in the control group(χ^(2)=6.709,P=0.010).Follow-up until August 2021,with a mean follow-up time of 33 months and 10 deaths during follow-up in the observation group,and a mean follow-up time of 31 months and 14 deaths during follow-up in the control group.Survival analysis of the patients was performed by the Kaplan-Meier method,and the survival rate of the observation group was 70.59%(24/34),which was higher than 57.58%(19/33)in the control group,but the difference was not statistically significant(χ^(2)=0.732,P=0.392).Conclusion The efficacy of paclitaxel liposome and paclitaxel injection in the treatment of advanced ovarian cancer is comparable,but paclitaxel liposome is safer than paclitaxel injection,the incidence of adverse effects is lower,the quality of life of the patients after chemotherapy is higher,and the survival time is longer.